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Abstract The myeloproliferative neoplasms (MPNs) are a
group of clonal hematological malignancies characterized
by a hypercellular bone marrow and a tendency to develop
thrombotic complications and to evolve to myelofibrosis
and acute leukemia. Unlike chronic myelogenous leukemia,
where a single disease-initiating genetic event has been
identified, a more complicated series of genetic mutations
appear to be responsible for the BCR-ABL1-negative
MPNs which include polycythemia vera, essential throm-
bocythemia, and primary myelofibrosis. Recent studies
have revealed a number of epigenetic alterations that also
likely contribute to disease pathogenesis and determine
clinical outcome. Increasing evidence indicates that alter-
ations in DNA methylation, histone modification, and
microRNA expression patterns can collectively influence
gene expression and potentially contribute to MPN patho-
genesis. Examples include mutations in genes encoding
proteins that modify chromatin structure (EZH2, ASXL1,
IDH1/2, JAK2V617F, and IKZF1) as well as epigenetic
modification of genes critical for cell proliferation and
survival (suppressors of cytokine signaling, polycythemia
rubra vera-1, CXC chemokine receptor 4, and histone
deacetylase (HDAC)). These epigenetic lesions serve as
novel targets for experimental therapeutic interventions.
Clinical trials are currently underway evaluating HDAC
inhibitors and DNA methyltransferase inhibitors for the
treatment of patients with MPNs.
Keywords Myeloproliferative neoplasm.Histone
deacetylase inhibitor.DNA methyltransferase inhibitor.
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Introduction
Myeloproliferative neoplasms (MPNs) represent a diverse
set of hematologic malignancies that have received
intense scientific investigation in recent years with a
goal of developing novel disease modifying strategies. In
2 0 0 8 ,t h eW o r l dH e a l t hO r g a n i z a t i o n( W H O )r e v i s e dt h e
classification of hematologic malignancies to reflect new
molecular insights into the pathogenesis of these disor-
ders. Currently, the MPNs include chronic myelogenous
leukemia (CML), polycythemia vera (PV), essential
thrombocythemia (ET), primary myelofibrosis (PMF),
systemic mastocytosis, chronic eosinophilic leukemia
not otherwise specified, chronic neutrophilic leukemia
and “MPN, unclassifiable”; CML, PMF, PV ,a n dE T
represent the four major clinical entities and will be the
subject of this review (Tefferi et al. 2007b).
CML is distinct among the MPNs in that it is defined by
a specific cytogenetic abnormality (Philadelphia chromo-
some) involving a balanced translocation between the long
arms of chromosomes 9 and 22 [t(9;22)(q34;q11)]. The
gene fusion product resulting from this translocation, BCR-
ABL1, gives rise to a constitutively activated and unregu-
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DOI 10.1007/s13148-011-0050-6lated cytoplasmic tyrosine kinase that causes uncontrolled
proliferation and differentiation of hematopoietic cells
(Deininger et al. 2000). The molecular understanding of
this pathway led to development of imatinib mesylate
(Gleevec)—an oral BCR-ABL1 inhibitor—which has rev-
olutionized the treatment of this MPN. In the International
Randomized Study of Interferon plus cytosine arabinoside
and STI571, imatinib therapy was found to induce a
complete cytogenetic remission in 76% of CML patients
versus 15% of patients in the interferon arm leading to a 6-
year overall survival of 88% (O’Brien et al. 2003;
Hochhaus et al. 2009). In contrast to CML, pharmacologic
interventions for the other common Philadelphia chromo-
some (Ph-) negative MPNs (PMF, ET, and PV) have not
been shown to significantly alter disease progression and
overall survival (Mascarenhas 2009).
In 2005, an activating point mutation (V617F) in the
autoinhibitory region of the JAK2 tyrosine kinase was first
documented in 96%, 50%, and 50% of patients with PV ,E T ,
and MF, respectively. JAK2V617F has served as a target for
the development of a number of tyrosine kinase inhibitors
(Baxter et al. 2005; James et al. 2005; Kralovics et al. 2005;
Levine et al. 2005). These novel agents have been tested in
phases I, II, and III studies and as a class have been
effective in palliating the constitutional symptoms and
reducing symptomatic splenomegaly in the majority of
patients (Pardanani et al. 2010a, b; Santos et al. 2010;
V erstovsek et al. 2009, 2010; Hexner et al. 2009; Moliterno
et al. 2009). However, these agents have to date not been
shown to significantly improve cytopenias, restore normal
bone marrow morphology, and induce cytogenetic remis-
sions in MF patients. In fact, molecular responses, as
demonstrated by significant reduction in the JAK2V617F
allele burden, have not been achieved. Thus, newer
therapies directed against epigenetic, immunological, and
molecular alterations of these Ph-negative MPNs are
necessary, and many are currently being evaluated in
clinical trials. In this review, we discuss epigenetic alter-
ations in the Ph-negative classic MPNs, specifically
focusing on epigenetic therapies as they relate to the
underlying pathophysiology of these blood cancers.
Philadelphia chromosome negative classic MPNs
The MPNs are collectively characterized by a hyper-
proliferative bone marrow and excessive myeloid cell
production. An increased risk for venous and arterial
thrombosis and transformation to acute leukemia exist and
pose a serious threat of morbidity and mortality to patients.
Cachexia, fatigue, global weakness, progressive spleno-
megaly, and constitutional symptoms (fever, night sweats,
and weight loss) can plague patients with the various MPNs
and are particularly troublesome in MF. Although elevated
peripheral blood counts typify ET and PV ,M Fi sm o s t
often characterized by anemia and thrombocytopenia.
Standardized diagnostic criteria, validated risk stratifica-
tion schema, and response criteria to therapeutic inter-
vention exist for these related disorders which have
recently been created to facilitate the evaluation of
potential new therapeutic modalities (Dupriez et al.
1996;B a r o s ie ta l .2005;T e f f e r ie ta l .2006, 2007b;
Passamonti et al. 2008; Cervantes et al. 2009).
Polycythemia vera
PVis defined by an increase in red cell mass in the absence
of conditions that induce secondary erythropoiesis and
specific diagnostic criteria exist to aid in confirming the
diagnosis (Thiele and Kvasnicka 2009). The average age of
onset is 60–65 years with an annual incidence ranging from
0.5 to 2.6 cases per 100,000 persons per year (Hoffman
2005). Patients with PV have been found to have a 1.6-fold
higher mortality than control populations with the main
causes of mortality and morbidity being arterial and venous
thrombosis, hemorrhage, evolution to MF, and leukemic
transformation (Hoffman 2005). PVis thought to arise from
a multipotent hematopoietic progenitor cell or stem cell.
Nearly 95% of patients express the JAK2V617F mutation
(James et al. 2005; V erstovsek et al. 2006). Presently,
treatment for low-risk individuals (<60 years of age and no
history of thrombosis) is low-dose aspirin and phlebotomy
to maintain the hematocrit below 45% for men and 42% for
women. In higher-risk individuals, cytoreductive therapy
such as hydroxyurea and interferon-alpha has been used
with the goals to reduce the risk of thrombosis, normalize
peripheral blood counts, decrease splenomegaly, and ame-
liorate hypercatabolic and constitutional symptoms
(Scherber and Mesa 2011).
Essential thrombocythemia
ET, the most common MPN in the USA, is defined by a
platelet count greater than 450,000×10
9/L (changed from
600,000×10
9/L in 2008 WHO classification update) in the
absence of any other MPN or reason for reactive thrombo-
cytosis (Tefferi et al. 2007b). Patients with ET generally
have a similar age-matched median survival for the first
decade after diagnosis that can shorten thereafter usually
secondary to thrombosis or hemorrhage (Wolanskyj et al.
2006). In approximately 50% of patients with ET,
JAK2V617F is expressed and in comparison to PV , the
allele burden is lower (James et al. 2005). Like PV ,
treatment consists of aspirin and cytoreductive agents such
as hydroxyurea or anagrelide for patients at high risk for
thrombosis. Approximately 10% of ET patients over the
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ET-related myelofibrosis) with clinical features essentially
indistinguishable from primary myelofibrosis (Wolanskyj
et al. 2006).
Primary myelofibrosis
PMF is the least common of the classic Ph-negative MPNs
and has the worst prognosis with a median survival of 3–
5 years from the time of diagnosis (Rozman et al. 1991;
Tefferi 2000). The annual incidence is 0.2–1.5 cases per
100,000 persons per year with predominance in males over
50 years of age. The JAK2V617F mutation is found in
about half of patients with PMF (James et al. 2005).
Myelofibrosis, arising from a background of polycythemia
vera or essential thrombocythemia, is denoted post-PV/ET
MF, and the treatment approach remains the same as PMF.
Collectively these conditions are referred to simply as MF.
Patients with MF can be risk stratified for risk of death
from transformation to acute leukemia or catastrophic
thrombosis and complications of portal hypertension by
various risk stratification systems that are used mostly for
research purposes in deciding appropriate treatment options
(Passamonti et al. 2010; Dupriez et al. 1996; Dingli et al.
2006; Tefferi et al. 2007a; Cervantes et al. 2009; Tam et al.
2009). Therapeutic approaches for the treatment of MF
include immunomodulatory agents such as thalidomide and
lenalidomide in combination with prednisone, which have
response rates of 20–40% (Mesa et al. 2003, 2010).
Androgens have also been used to selectively manage the
anemia associated with MF, with response rates close to
40% (Cervantes et al. 2005). A few prospective studies
have used erythropoiesis-stimulating agents with
conflicting results (Cervantes et al. 2006; Tsiara et al.
2007). Chemotherapeutic agents including hydroxyurea,
melphalan, busulfan, and 2-chlorodeoxyadenosine have
also been used to control the myeloproliferative aspects of
the disease (Chang and Gross 1988; Tefferi et al. 1997; Petti
et al. 2002). The only present approach capable of curing
MF is allogeneic hematopoietic stem cell transplantation,
which must be evaluated on a case-by-case basis and
balanced against considerable transplant-related morbidity
and mortality (Kroger et al. 2009; Rondelli et al. 2010).
The effects of Janus kinase 2 inhibitors on Ph-negative
MPN patients
In 2005, with the discovery of the JAK2V617F mutation, a
substantial breakthrough in the understanding of the
pathogenesis of Ph-negative MPNs led to the rapid
development of new class of agents. Within a year,
preclinical studies demonstrated that a G to T point
mutation in exon 14 of the JAK2 tyrosine kinase gene
(valine-to-phenylalanine at codon 617) was associated with
the development of an MPN-like phenotype—erythrocyto-
sis, leukocytosis, splenomegaly, and eventually changes
resembling transformation to myelofibrosis (Bumm et al.
2006; Lacout et al. 2006; Wernig et al. 2006; Zaleskas et al.
2006). In vivo murine studies rapidly spawned the
development of new oral small molecule inhibitors
designed to inhibit the JAK2V617F-induced constitutively
active signaling pathway. For the first time in decades, a
renewed sense of optimism for producing effective
disease modifying agents for the treatment of MPNs
brought laboratory investigators and clinician scientists to
t h es a m et a b l e .
One agent, INCB018424 (Incyte), a potent and selective
JAK1/JAK2 inhibitor, which demonstrated preclinical
benefits in a JAK2V617F expressing MPN mouse model,
recently completed a phase 1/2 clinical trial (Quintas-
Cardama et al. 2010; V erstovsek et al. 2010). At the 15-mg
twice-daily dosing, 17 of 33 MF patients with or without
the JAK2V617F mutation (52%) had an objective clinical
response (>50% decrease in splenomegaly) for 12 months
and significant reduction in symptoms such as weight loss,
fatigue, night sweats, and pruritus. Grade 3 or 4 adverse
events occurred in less than 10% of patients and are mainly
due to myelosuppression. This agent is being investigated
in a randomized, double-blind, placebo-controlled phase III
study to assess overall clinical efficacy in spleen reduction
and improvement in MF-related disease symptoms as
measured by an MF-specific quality-of-life tool, and the
results of this trial are expected to be revealed in the latter
part of 2011 (Scherber and Mesa 2011; Mesa et al. 2009a).
Other JAK2 inhibitors undergoing clinical evaluation
include the non-specific multi-tyrosine kinase inhibitor
CEP-701 (Cephalon), the selective JAK2 inhibitor
SB1518 (SBIO), TG101348 (TargeGen), and CYT387
(YM BioSciences; Pardanani et al. 2010a, b; V erstovsek et
al. 2009). Studies with newer agents directed against the
constitutive tyrosine kinase activity induced by the
JAK2V617F mutation are promising but still limited.
While offering significant improvement in clinical symp-
toms, these agents do not appear to alter disease
progression which has led to the continued interest in
investigating alternative targeted therapies such as mam-
malian target of rapamycin inhibitors, immunomodulato-
ry drugs, and anti-fibrosing agents which act to exploit
additional aberrant pathways and proposed mechanisms
of disease pathobiology (Scherber and Mesa 2011; Hoffman
and Rondelli 2007).
Other gene mutations influencing the MPN phenotype
have also been identified. Mutations in exon 12 of JAK2
have been described in a fraction of JAK2V617F-negative
PV patients (Scott et al. 2007). Somatic activating muta-
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W515L/K occur in 10% of patients with PMF and 8% of
JAK2V617F-negative ET, and in some patients, the MPL
and JAK2V617F mutation can coexist (Pardanani et al.
2006; Beer et al. 2008; V annucchi et al. 2008). These
mutations are of low frequency and unlikely to serve as
worthy drug targets.
Epigenetic alterations involved in the pathogenesis
of Ph-negative MPNs
The biologic events leading to the initiation and progression
of MPNs are likely not only caused by the acquisition of
genetic mutations, such as the JAK2V617F mutation, but
may also due to epigenetic changes that do not affect the
primary sequence of DNA but rather alter gene expression
by remodeling chromatin. Chromatin remodeling is accom-
plished primarily through two main mechanisms: (a) post-
translational modification of histones, such as methylation,
acetylation, phosphorylation, ADP-ribosylation glycosyla-
tion, and ubiquitination. Among all the types of histone
modifications, methylation and acetylation at specific lysine
residues are considered crucial histone marks affecting
chromatin structure and gene expression (Kouzarides
2007). (b) DNA methylation with the addition of a methyl
group to cytosine–phosphate–guanine (CpG) dinucleotide
repeats within gene regulatory DNA sequences modulates
the transcription of various genes (Metivier et al. 2008).
The attachment of a methyl group to the five-carbon
position of cytosine base located 5′ to a guanosine base in
the CpG dinucleotide islands of gene promoter sites
influences the access of transcriptional machinery to DNA
(Mani and Herceg 2010). This enzymatic process is
regulated by DNA methyltransferases (DNMT). DNMT3A
and DNMT3B are involved in de novo DNA methylation
and DNMT1 in the maintenance of DNA methylation. The
methylation status of a particular gene is an important
determinant of gene expression, and both DNA hypome-
thylation and hypermethylation patterns have been impli-
cated in the pathogenesis of many cancer types (Feinberg
and Tycko 2004; Esteller 2007).
The addition of acetyl groups to lysine residue at the N
terminus tail of histone proteins and the addition of methyl
groups to lysine and arginine residues represent the best
characterized histone modifications. The specific patterns of
histone modifications define a code that dictates the
dynamic recruitment of various transcription factors and
the varied post-translational modification of histones by
histone acetyl transferases (HA Ts), deacetylases (HDACs)
or methyl transferases (HMTs), protein arginine methyl-
transferases (PRMTs), and DNA methyltransferases
(DNMTs). These networks collectively play a critical role
in modulating histone/histone and DNA/nucleosome inter-
actions (Becker and Horz 2002). Dysregulation of these
processes can result in silencing of tumor suppressor and
cell differentiation genes, thereby promoting cell survival
by blocking apoptosis and senescence and contributing to
malignant transformation (Jenuwein and Allis 2001;E s t e l l e r
2008; Kondo et al. 2008). The complex interaction among
these enzymes and the nucleosome result in a cumulative
effect on chromatin structure. Figure 1 depicts the many
varied and overlapping influences of HDACs, HMTs,
DNMTs, and HA Ts directly on histone and DNA structure
as well as the co-repression or activation of transcription
factors. The shift in the balance of activity of one or more of
these integral regulatory proteins will determine the tran-
scriptional fate of numerous genes. Also indicated in the
cartoon are two classes of therapeutic agents (histone
deacetylase inhibitor (HDACi), DNMT1) which will be
discussed in subsequent sections that can modify the
epigenome in favor of overcoming transcriptional repression.
Other less well-characterized epigenetic modifications
include post-transcriptional regulation of gene expression
by a heterogeneous class of non-coding RNAs such as
microRNAs (miRNAs) (Berdasco and Esteller 2010).
MiRNAs bind to the 3′ untranslated region (3′UTR) of
target mRNAs and either repress protein translation or
cause mRNA degradation (Ambros 2004). MiRNAs
(miR21, miR24, miR144, miR146a, miR150, miR155,
miR221, miR222, miR223, miR451) play fundamental
roles in the normal differentiation and activity of hemato-
poietic cells (Havelange and Garzon 2010). Data from both
in vitro and in vivo studies indicate that miRNAs are
important regulators of hematopoiesis and play a role in the
pathogenesis of some acquired hematologic disorders,
functioning either as tumor suppressors (miR-15/16)o ra s
oncogenes (miR-17-92 cluster; Lawrie 2007). Microarray
studies have defined miRNA signatures in hematopoietic
cell lineages and related hematologic malignancies (Calin et
al. 2004, 2005; Bruchova et al. 2007; Georgantas et al.
2007), and comparison of normal and patient samples has
revealed aberrantly expressed miRNA that reflect a disease
specific signature (Debernardi et al. 2007; Gramantieri et al.
2007; Meng et al. 2007; V enturini et al. 2007). Changes in
miRNA expression can occur through different mechanisms
including transcriptional deregulation, epigenetic altera-
tions, gene mutations, DNA copy number abnormalities,
and impaired miRNA processing (Deng et al. 2008). These
disease specific-miRNA epigenetic signatures may provide
a basis for new therapeutic interventions by specifically
targeting miRNA expression.
MiRNA expression profiling of megakaryocytes in PMF
but not ET has revealed that in the pre-fibrotic form of PMF,
autonomous proliferation of the megakaryocytic lineage is
associated with significant accumulation of miR-146b as
compared to normal megakaryopoiesis (Hussein et al. 2009).
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megakaryocytes which appears to be one of the underlying
defects associated with disease progression. Recently,
Girardot et al. 2010 r e p o r t e dt h a ti naf r a c t i o no fM P N
patient platelets, Mir 28 negatively regulates MPL
expression. Mir 28 targets the 3′UTR region of MPL
and inhibits its translation as well as other proteins
potentially involved in megakaryocyte differentiation
including E2F6, a transcription factor belonging to the
E2F family and ERK2.
Two broad categories of epigenetic alterations in MPN
pathophysiology have been observed. The first involves
alterations in genes that encode proteins which influence
chromatin structure. Alterations in TET2, ASXL1, EZH2,
IDH1/2, JAK2V617F,a n dIKZF1 gene functions are
examples of this first category and can lead to epigenetic
dysregulation. TET2, ASXL1, IDH1/2, and EZH2 gene
mutations are found alone or in combination with JAK2 or
MPL mutations and influence the epigenetic regulation of
transcription resulting in the possible silencing of putative
tumor suppressor genes in MPNs. The second category
includes the promoter site of genes critical for cell survival,
differentiation, and proliferation. Examples of this group of
genes in MPNs are provided in Table 1. We will now review
Fig. 1 Active transcription is
associated with hyperacetylation
of histones, when an acetyl
group (Ac) is added to specific
lysines residing within the N
terminal region of histones. The
affinity between histone and
DNA is reduced, leading to an
open chromatin conformation
that allows transcription factors
(TF) and RNA polymerase to
access the promoter of the target
genes. Additionally, methylation
of certain lysines on histones
(H3K4, H3K36, and H3K79)
located at promoter regions also
leads to active transcription. In
contrast, DNA methylation and
hypoacetylation and/or methyla-
tion of certain other lysines on
histones (H3K9, H3K27, and
H4K20 residues) are associated
with gene repression from for-
mation of relatively condensed/
inactive chromatin. These mod-
ifications are catalyzed by a
number of chromatin-modifying
enzymes including DNA meth-
yltransferases (DNMTs), histone
acetyltransferases (HATs)/histone
deacetylases (HDACs), histone
methyltransferases (HMTs), and
histone demethylases (HDMs).
The expression of transcription-
ally inactive genes can be upre-
gulated by exposure to DNMT-
inhibitors and HDAC inhibitors
Clin Epigenet (2011) 2:197–212 201the most current understanding of epigenetic dysregulation
in Ph-negative MPNs.
Category I—gene alterations leading to epigenetic
deregulation of Ph-negative MPNs
TET2
Mutations involving the ten to 11 translocation-2
(TET2) family gene located in the minimal loss of
heterozygosity region at 4q24 have been identified in
several myeloid malignancies (Delhommeau et al. 2009).
The exact function of TET2 is not yet clear, but it appears
to act as a tumor suppressor gene (Schaub et al. 2010;
Delhommeau et al. 2009). Homozygosity for TET2
mutations as a result of uniparental disomy or deletion
of the TET2 locus does not appear to confer a
proliferative advantage to hematopoietic progenitor cell
clones which would argue against a role as a tumor
suppressor gene (Schaub et al. 2011). TET2 is a member
of the α-ketoglutarate-dependent enzyme family that
catalyzes the conversion of 5-methylcytosine of DNA to
5-hydroxymethylcytosine and induces subsequent DNA
demethylation (Ito et al. 2010; Tahiliani et al. 2009).
TET2 mutations have been reported in almost all coding
regions including missense, nonsense, or frameshift
mutations. Moreover, these mutations are not exclusively
bi-allelic (both copies of TET2) and therefore considered
TET2 loss of function mutations (Delhommeau et al.
2009). TET2 loss of function would be anticipated to
result in DNA hypermethylation which has been recently
reported in acute myeloid leukemia (AML) blast cells.
Overall, the frequency of TET2 mutations in Ph-negative
MPNs has been reported to be 12–17% (Delhommeau et al.
2009; Tefferi et al. 2009b). A higher TET2 mutation
frequency has been detected in older MPN patients
(>60 years) and has been shown to be highly correlated
with JAK2V617F allele burdening these patients (Tefferi et
al. 2009b). In fact, studies support the role of TET2 in
JAK2V617F-positive PV as not a disease-initiating event
preceding the acquisition of the JAK2 mutation, but as a
latter event that can confer a proliferative advantage to
the JAK2V617F-bearing clone (Swierczek et al. 2010;
Delhommeau et al. 2009). However, other studies utilizing
colony-forming assays failed to demonstrate a consistent
temporal relationship between the acquisition of the
somatic mutations of TET2 and JAK2 (Schaub et al.
2010). TET2 mutations have largely not been uniformly
shown to have prognostic significance; no influence was
demonstrated on survival, rate of leukemic transformation,
or thrombotic tendency in MPN patients (Hussein et al.
2010; Tefferi et al. 2009a, b). In contrast, TET2 mutations
have been identified in blast phase MPN samples and not
observed in the paired background MPN samples of both
JAK2 wild-type and mutant MPNs obtained prior to blastic
transformation (Abdel-Wahab et al. 2010a). This finding
would suggest that the acquisition of TET2 mutations may
be a possible step in MPN leukemic transformation.
ASXL1
ASXL1 is one of three mammalian homologs of the
additional sex combs gene in Drosophila (69). The ASXL1
gene is located on chromosome 20q11 and encodes an
enhancer of the trithorax group (trxG) and Polycomb group
Table 1 List of genes in which expression can be altered by epigenetic mechanisms in MPNs
Gene Abbreviation MPN subtype Reference
Calcitonin A CALCA ET, PV , PMF Ihalainen et al. (1994)
V-abl Abelson murine leukemia viral oncogene homolog 1 ABL1 ET, PV , PMF Aviram et al. (2003)
Cyclin-dependent kinase inhibitor 2A p14
ARF CML Nagy et al. (2003); Kumagai et al.
(2005); Jost et al. (2007) p16
INK4a CML
Cyclin-dependent kinase inhibitor 2b p15
INK4b MF-BP Wang et al. (2002)
Secreted Frizzled-related protein 1 SFRP1 CML Bennemann et al. (2010);
Pehlivan et al. (2009)
Secreted Frizzled-related protein 2 SFRP2 ET, PV , PMF Bennemann et al. (2010)
Wnt inhibitory factor-1 WIF-1 ET, PV , PMF Suzuki et al. (2007)
Suppressor of cytokine signaling 1 SOCS1 ET, PV , PMF, MF-BP Jost et al. (2007); Capello et al. (2008)
Suppressor of cytokine signaling 3 SOCS3 PMF Fernandez-Mercado et al. (2008);
Fourouclas et al. (2008)
Polycythemia rubra vera protein 1 PRV1 ET, PV Jelinek et al. (2007)
C-X-C chemokine receptor type 4 CXCR4 PMF Bogani et al. (2008)
Retinoic acid receptor beta 2 RARβ2* PMF Jones et al. (2004); Jost et al. (2007)
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et al. 2003). The PcG proteins (repressors) and trxG
proteins (activators) serve to regulate gene expression of
homeotic genes, such as Hox genes via histone methylation
(Fisher et al. 2010a). PcG and trxG proteins function at the
level of chromatin by forming multi-protein complexes:
which are the three PRC1, Polycomb repressor complex 2
(PRC2), PhoRC and SET-1-like complex, BRM, and MLL
supercomplex, respectively (Baskind et al. 2009). These
complexes work together to establish and maintain meth-
ylation marks primarily on the tail of histones. Mammalian
PcG and trx genes display hematopoietic lineage and
differentiation stage-specific expression patterns and are
required for normal hematopoiesis. Mammalian ASXL
proteins are predicted to have dual activator/repressor
functions depending on their cellular context. An ASXL1
knockout mouse model is characterized by a defect in
frequency of differentiation of both myeloid and lymphoid
cells, without an effect on hematopoietic stem cells and
does not result in a myelodysplastic or leukemic phenotype
(Fisher et al. 2010b). This would seem to indicate that
ASXL1 mutations alone are not sufficient to induce
malignant transformation.
ASXL1 mutations have been documented in myelodys-
plastic syndrome (MDS; 10%) and chronic myelomono-
cytic leukemia (40%) patients and most recently in 8% of
MPN patients that were all negative for JAK2V617
(Carbuccia et al. 2009). The ASXL1 mutations were also
found in the CD34
+ cell population supporting the
principle of a primitive hematopoietic stem as the origin
of the MPN clone and further suggesting that acquisition
of ASXL1 mutations can occur early in MPN pathogenesis.
Although the ASXL1 mutations are associated with poor
overall survival and increased risk for transformation to
blast crisis in chronic myelomonocytic leukemia patients,
it is not yet clear what influence it has on the behavior of
Ph-negative MPNs.
EZH2
Mutations involving the enhancer of zeste homolog 2
(EZH2) gene located on chromosome 7q36.1, which
encodes the catalytic component of the histone methyl-
transferase PRC2 have also been described in MPN
patients (Stegelmann et al. 2010). PRC2 is a multi-
protein enzyme complex responsible for the trimethylation
of lysine 27 on histone H3 (H3K27me3; Cao and Zhang
2004; Simon and Lange 2008). The PRC2 complex
contains multiple subunits: EZH2, SUz12, EED, and
YY1. PRC2 can also recruit other Polycomb complexes,
DNMTs, and HDACs to the gene site resulting in
chromatin compaction and additional repressive activity
(Chase and Cross 2011).
Activating and inactivating mutations of EZH2 have
been reported in human malignancies. The EZH2 Y641
mutation (within the SET domain) which is found in
lymphoma cells results in a gain of function with increased
levels of H3K27me3 (Morin et al. 2010). The mutations
associated with myeloid malignancies are thought to result
in loss of histone methyltransferase activity. Forty-nine
EZH2 mutations have been found in 42 individuals out of
614 patients with myeloid disorders (Ernst et al. 2010).
Thirteen percent of MF patients in this cohort harbored an
EZH2 mutation. A total of ten EZH2 mutations were
identified in exons involving deletions, insertions, and
missense mutations in patients with PMF, post-PV/ET MF,
and MPN-associated acute myeloid leukemia. Microarray
and SNP analysis did not show association with copy
number alterations or uniparental disomy. Additionally, no
association was seen with JAK2V617F allele burden.
Degree of splenomegaly and leukocytosis was clinical
findings found to be statistically associated in MPN patients
expressing EZH2 mutations. Upregulation of EZH2 gene
expression has been documented in MPNs, most frequently
in PMF patients suggesting a potential role of tumor
suppressor gene silencing as a mechanism in disease
progression (Skov et al. 2010a). Additionally, EZH2 and
ASXL1 mutations were not found to be mutually exclusive
events in MPNs. Retrospective analysis of the presence of
EZH2 mutations in archived MPN bone marrow samples
has not been shown to have prognostic significance in PMF
patients (Abdel-Wahab et al. 2010b).
Three-deazaneplanocin A (DZNep) is a carbocyclic
adenosine analog that inhibits s-adenosylhomocysteine
hydrolase and results in the accumulation of s-adenosylho-
mocysteine, disrupting methylation of targets by EZH2
(Chase and Cross 2011). Although the effects of DZNep are
global and not specific to EZH2, this drug has been tested
as a single agent in solid tumor cell lines and in
combination with a HDACi in primary AML cells (Fiskus
et al. 2009). The combination of this agent with the pan-
HDACi, LBH589 (Panobinostat, Novartis), was shown in
vitro to selectively induce apoptosis in AML primary cells
and not normal CD34
+ cells. This effect was correlated with
reduction in EZH2 protein level and induction in p16, p21,
and p27 gene expression. Combined therapy in a NOD/
SCID mouse model with HL-60 AML led to an improve-
ment in survival when compared to each agent alone
(Fiskus et al. 2009). This compound is currently being
investigated in early phase clinical trials.
Expression of miR-101-1 and 101-2 which negatively
regulate EZH2 has been shown to be decreased in MPNs
and displayed an inverse relationship with EZH2 mRNA
expression (Swierczek et al. 2011). This may provide an
additional mechanism for EZH2 gene dysregulation and
contribute to MPN disease progression and disease severity.
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Isocitrate dehydrogenase 1 and 2, IDH1 and IDH2, located
on chromosome 2q33.3 and 15q26.1, respectively, encode
NADP
+-dependent enzymes that catalyze oxidative decar-
boxylation of isocitrate to α-ketoglutarate (Tefferi et al.
2010). The IDH mutant has decreased affinity for isocitrate
and instead converts α-ketoglutarate to hydroxyl-glutarate
which has been implicated in malignant transformation
(Dang et al. 2009). IDH gene mutations have been
documented in solid tumors and de novo AML (Chou et
al. 2010; Y an et al. 2009). A recent study in AML has
revealed that the presence of IDH1/2 mutations result in
production of 2-hydroxyglutarate and is associated with a
specific global DNA hypermethylation signature (Figueroa
et al. 2010). Both IDH1/2 mutations and TET2 mutations
lead to similar hypermethylation signatures and patterns of
impaired myeloid differentiation and increased expression
of stem cell markers. Additionally, it has been shown that
IDH1/2 mutations generate impaired enzymatic activity of
α-ketoglutarate-dependent TET2 protein and result in
increased stem cell/progenitor cell marker expression
(Figueroa et al. 2010). Thus, the expression of IDH1/2
mutations can lead to a TET2-dependent epigenetic effect.
IDH1/2 mutational frequency in MPNs is approximately
0.8%, 1.9%, and 4.2% for ET, PV , and PMF, respectively
(Tefferi et al. 2010). Thirty-eight IDH 1/2 mutations have been
discovered in a large screening study of MPN patients and can
coexist equally with mutations in JAK2, MPL,a n dTET2
(Tefferi et al. 2010). The types of IDH1/2 mutations seen in
MPNs are distinctly different than the ones observed in brain
tumors and overlapped with those documented in AML and
include IDH1-R132, IDH2-R140, and IDH2-R172. Over 21%
of patients with blast phase-related MPN carry an IDH1/2
mutation, and this was irrespective of JAK2V617F status
(Green and Beer 2010; Pardanani et al. 2010c). This appears
to indicate that IDH1/2 mutations can also influence the
transformation of MPN to blast phase disease.
Interestingly, leukemic blasts and progenitor cells can
possess both mutated IDH2 and JAK2V617F, and in other
patients with MPN-transformed leukemia, the mutated
IDH1/2 may be present in blasts with wild-type JAK2 and
absent in the progenitor cells with JAK2V617F (Green and
Beer 2010). These data raise the possibility of the presence
of two subclones originating from a yet unidentified primary
clone or two independent competing clones arising in the
same individual. Further studies are needed to further clarify
these findings and determine their possible significance.
IKZF1
Ikaros is a Kruppel-like zinc finger transcription factor that
is integral to the development of normal hematopoiesis and
is encoded by the Ikaros family zinc finger 1 (IKZF1) gene
located at 7p.12 (Georgopoulos 2002; Westman et al. 2002).
The exact mechanism by which this mutation influences
chromatin remains unclear. IKZF1 influences maturation
and differentiation of a variety of cell types at different
stages of development including those of the hematopoietic
system (Westman et al. 2002). IKZF1 interacts with the
histone deacetylase repressor complexes NURD (HDAC1
and 2) and SIN3 which likely exerts a repressive influence
on genes important in myelopoiesis.
IKZF1 mutations were first identified in cells from Ph-
positive acute lymphocytic leukemia patients and are
believed to play a role in leukemic transformation (Iacobucci
et al. 2009). In a study of blast phase MPN patients, a
recurrent loss of chromosomal region 7p.12 led investiga-
tors to the discovery of IKZF1 deletions in 21% of patients
with blast phase MPN and only 0.2% of chronic phase
MPN patients, providing a very compelling argument for a
role of IKZF1 in leukemic transformation (Jager et al.
2010). IKZF1 mutants are associated with increased STA T5
expression and resultant activation of the JAK–STA T
pathway (Jager et al. 2010). IKZF1 mutation appears to be
a late event occurring after the acquisition of JAK2V617F,
and its exact pathogenetic role in MPN leukemic transfor-
mation remains unclear (Jager et al. 2010).
JAK2V617F
Genome-wide methylation pattern studies on MPN patient
samples demonstrate a distinct chromatin altered pattern in
PMF when compared to PV/ET patient samples (Nischal et
al. 2010). Both hyper- and hypomethylated loci were found
in neutrophils of PMF patients. Hypomethylated promoter
sites involved genes responsible for cytokine signaling and
MAP kinases. The presence of JAK2V617F additionally
was found to influence the degree of DNA hypomethyla-
tion and supports a proposed role for JAK/STA T pathway
influence on the methylome and ultimately on gene
transcription and disease phenotype (Nischal et al. 2010).
Recently, alternative pathways by which JAK2V617F
might affect hematopoiesis have been identified, and
Dawson and co-workers found that 35% of the JAK2
regulated genes did not contain a STA T5 binding site
(Dawson et al. 2009). This group determined that JAK2 can
be localized to not only the cytoplasm but also the nucleus
where it phosphorylates histone H3 at tyrosine residue 41
(Y41). H3Y41 results in release of the transcriptional
repression by heterochromatin protein 1α from chromatin.
Furthermore, Liu and co-workers have shown that
JAK2V617F phosphorylates and downregulates the activity
of PRMT5, an arginine methyltransferase discussed below
(Liu et al. 2011). This event leads to a gain of function that
affects the gene expression pattern and the behavior of
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arginine methylation.
PRMT5
The type II arginine methyltransferase PRMT5 catalyzes the
symmetric dimethylation of arginine residues on histones H2a,
H3, and H4 (Branscombe et al. 2001). PRMT5 is a target of
JAK2-mediated phosphorylation and in JAK2V617F express-
ing cells leads to downregulation of PRMT5 activity and
decreased global histone methylation. Forced PRMT5 gene
over-expression in primary PV CD34+ cells results in a
reduction in cell proliferation and differentiation and supports
the role of downregulated PRMT5 activity via JAK2 mediated
phosphorylation in the molecular pathogenesis of PV .T h i s
provides a very interesting pathogenetic view of JAK2-
mediated chromatin modification as a downstream target of
the activated tyrosine kinase pathway.
Category II—individual genes affected by epigenetic
modification in MPN
SOCS
Suppressors of cytokine signaling (SOCS1, SOCS2, and
SOCS3) are negative regulators of the JAK–STA T pathway
and are both induced by and act in a negative feedback loop to
downregulate JAK/STA T signaling (Greenhalgh and Hilton
2001). Epigenetic silencing of SOCS1/3 is an additional
pathogenetic mechanism leading to cytokine signaling hyper-
sensitivity. SOCS1 hypermethylation has been reported in a
fraction of patients with Ph-negative MPNs and can be seen in
both JAK2V617F-positive and JAK2 wild-type patients (Jost
et al. 2007; Teofili et al. 2008). However, the methylation
pattern that was observed in these studies was noted in
SOCS1 exon 2 (also seen in normal control blood cells) but
not the gene promoter site and thus the relevance of this
observation to MPN pathogenesis is not evident. Hyper-
methylation of SOCS3 has been detected in PMF but not PV/
ET patients. A trend for lower SOCS3 expression in
JAK2V617F-negative PMF patients was noted in one study
(Fernandez-Mercado et al. 2008). SOCS methylation status
was not correlated with any identifiable clinical variables or
outcome (Fourouclas et al. 2008). SOCS2 silencing by
hypermethylation has also been shown in MPN-derived cell
lines as well as primary MPN cells and can coexist in cells
that carry the JAk2V617F mutation (Quentmeier et al. 2008).
SFRP1/2
Secreted Frizzled-related protein (SFRP) actively antago-
nizes the Wnt signaling pathway which is integral to the
maintenance and proliferation of hematopoietic stem cells
(Willert et al. 2003). Upregulation of the Wnt pathway and
downregulation of SFRP has been shown in other hemato-
logic malignancies. SFRP2 promoter hypermethylation was
detected in 27%, 30%, and 26% of PV , ET, and PMF patient
samples, respectively (Bennemann et al. 2010). Hyper-
methylation of SFRP-2 promoter site was not seen in any
cases of CML.
PRV-1
Over-expression of polycythemia rubra vera-1 (PRV-1)
mRNA, a GPI-linked protein expressed by neutrophils
of patients with ET/PV , has been shown to be inversely
r e l a t e dt ot h eC 3 0p r o m o t e r site methylation status
(Jelinek et al. 2007). PRV-1 (CD177) is a hematopoietic
cell surface receptor with yet unclear function normally
expressed on neutrophils and can be upregulated in
certain settings including, sepsis, pregnancy, and after
granulocyte colony-stimulating factor administration.
Although the mRNA transcript is over-expressed in all
patients with PV , the protein product is not and is
comparable to the level observed in normal control
neutrophils (Klippel et al. 2002). The JAK2V617F allele
burden was also inversely related to C30 methylation,
and a trend toward significance was appreciated with an
inverse relationship to JAK2V617F allele burden.
CXCR4
In MF, extramedullary hematopoiesis of CD34+ hema-
topoietic stem cells (HSC) in the spleen and other
organs is responsible for many of the signs and
symptoms attributed to this disease. This abnormal cell
trafficking from the bone marrow niche is believed to
be a result of reduced CD34+ cell expression of CXC
chemokine receptor 4 (CXCR4), leading to constitutive-
ly mobilized peripheral blood HSC (Rosti et al. 2007).
CXCR4 is a receptor for stromal-derived factor-1 (SDF-
1; CXCL12) and induces normal HSC and progenitor cell
chemotaxis to the marrow space. The CXCR4 receptor in
PMF cells, compared to normal controls, is susceptible to
epigenetic modification from hypermethylation of CpG
islands within its promoter region (Bogani et al. 2008).
Treatment with the demethylating agent 5-aza-2′-deoxy-
cytidine (5-AzaD; DEC) in vitro increased membrane
expression of CXCR4 and improved migration of CD34+
cells in the presence of SDF-1 (Shi et al. 2007).
Moreover, sequential treatment of PMF CD34+ cells
with 5-AzaD and trichostatin A (TSA), a HDAC
inhibitor, increased preferential homing of PMF CD34+
cells to the bone marrow and not the spleen of NOD/
SCID mice (Wang et al. 2009a, b). These agents also
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homozygous HPCs, and cells that contained chromosomal
abnormalities. Most recently, treatment with sequential 5-
azacytidine(5-Aza)/TSAinaJAK2V617F+PMFCD34+cell
transplantNOD/SCIDmouse model ledtodramaticreduction
in number of these cells suggesting potential use of these
agents in treating the mutated stem cell population in PMF
(Wang et al. 2010).
HDAC
The HDAC family consists of 18 genes, subdivided
into four classes based on their homology to yeast
ortholog. The HDACs can be divided into two families,
first is the Zn
2+-dependent HDAC family composed of
class I (HDACs 1, 2, 3 and 8), class II a/b (HDACs 4, 5,
6, 7, 9, and 10), and class IV (HDAC 11), and the second
is the NAD-dependent class III SIRTenzymes (Biancotto
et al. 2010). Histone acetylation is regulated by the
dynamic and antagonistic action of two classes of
enzymes, HDACs and HA Ts. HA Ts execute the transfer
of an acetyl group from acetyl Co-A to the ε-amino
group of lysine residues, whereas HDACs catalyze the
r e m o v a lo fa c e t y lg r o u p s .A cetylation of histones and
non-histone proteins can alter DNA–protein binding,
protein–protein interaction, and/or subcellular localiza-
tion. Considerable evidence indicates that the acetylation
status of histones and non-histone proteins play a key
role in the regulation of cellular signaling and disease
progression (Haberland et al. 2009;S p a n g ee ta l .2009).
For instance, global gene expression profiling of MPN
patient blood cells revealed HDAC gene deregulation
(Skov et al. 2010b). HDAC 9 and 11 gene over-expression
was documented in various MPN subtypes, and an
increase in HDAC 6 gene expression was observed
during MPN disease progression. These data support
the possible role of HDAC enzyme inhibition as a
treatment approach to MPNs.
Epigenetic therapy for Ph-negative MPNs
HDAC inhibitors
HDACi are a novel class of structurally diverse natural and
synthetic compounds that modulate a myriad of cellular
functions by inhibiting HDAC activity. The ability of
various HDACis such as LBH589 (Panobinostat, Novartis),
ITF2357 (Givonostat, Italfarmaco SpA), and suberoyla-
nilide hydroxamic acid (SAHA, Merck) to inhibit
JAK2V617F-positive HPCs has been examined (Table 2
lists and describes these agents as well as the DNA
methyltransferase inhibitors (DNMTi) currently being
evaluated for the treatment of MPN patients). ITF2357
was shown in vitro to inhibit the proliferation of
JAK2V617F cells by specifically decreasing the level of
JAK2V617F protein, without associated changes in
JAK2V617F mRNA levels, and inhibiting downstream
signaling such as phosphorylation of STA T-5 (Guerini et al.
2008). Exposure of JAK2V617F-expressing cell lines to
LBH589 has also been shown to result in the proteasomal
degradation of JAK2V617F via disruption of the
chaperone function of HSP90 and induced apoptosis in
these cells (Wang et al. 2009b). Cotreatment with
the JAK2 inhibitor TG101209 in both JAK2V617F-
expressing cell lines and primary CD34+ MPN cells led
to attenuated downstream JAK/STA T signaling and syn-
ergistic cytotoxicity that was selective to the malignant
clone but was not observed in normal CD34+ hemato-
poietic stem cells. Preclinical studies have demonstrated
the anti-proliferative activity of SAHA in JAK2V617F+-
expressing cell lines (Akada et al. 2010). Selective
reduction in the clonogenic growth of JAK2V617F+-
expressing colonies suggested specificity for mutated
JAK2-bearing cells. Using an established inducible
JAK2V617F+ knock-in mouse model for PV , treatment
with SAHAwas shown to reduce splenomegaly, normal-
ize hematocrit, and reduce the numbers of JAK2V617F-
Table 2 List of genes in which altered expression can lead to epigenetic deregulation in MPNs
Gene Abbreviation MPN subtype Reference
10–11 translocation-2 TET2 ET, PV , PMF, MF-BP Hussein et al. (2010); Schaub et al. (2010);
Tefferi et al. (2009b)
Additional sex combs like 1 ASXL1 ET, PMF, MF-BP Carbuccia et al. (2009)
Enhancer of zeste homolog 2 EZH2 MDS/MPN, PMF, MF-BP Ernst et al. (2010)
Isocitrate dehydrogenase 1 and 2 IDH1/2 ET, PV , PMF, MF-BP Green and Beer (2010); Pardanani et al.
(2010c); Tefferi et al. (2010)
Ikaros family zinc finger 1 IKZF1 MF-BP Jager et al. (2010)
Janus-associated kinase 2 JAK2V617F ET, PV , PMF, MF-BP Nischal et al. (2010); Dawson et al. (2009)
Protein arginine methyltransferase 5 PRMT5 PV Liu et al. (2011)
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provided a foundation for the use of chromatin-
modifying agents in clinical trials for MPNs (Table 3).
A phase II pilot study of ITF2357 at 50 mg orally twice
daily for 24 weeks in patients with JAKV617F-positive PV ,
ET, and PMF showed three major responses among 16 MF
patients treated (Rambaldi et al. 2010). This agent also
improved pruritus and reduced splenomegaly in 75% of
PV/ET and 38% of MF patients. A trend toward reduction
in JAK2V617F allele burden was observed. No major grade
III/IV adverse events were observed. LBH589 has been
evaluated in two phase I/II studies. In the first study, the
agent was used in both high-risk JAK2V617F-positive and
JAK2V617F-negative PMF and post-ET/PV MF patients
(Mascarenhas et al. 2009). This agent was associated with
improvements in anemia in two patients and significant
reduction in palpable splenomegaly. Thrombocytopenia was
found to be the DLT and the recommended phase II dose
was determined to be 25 mg given orally three times
weekly. In the second study among 12 patients with PMF or
post-ET/PV MF, four patients demonstrated reduction in
spleen size greater than 50% (DeAngelo et al. 2010). One
previously untreated JAK2V617F-positive patient demon-
strated a partial response according to IWG response
criteria. Three additional patients demonstrated clinical
improvement lasting ≥8 weeks. Four patients had stable
disease. Similar to the first study, the most common adverse
event was thrombocytopenia. Phase II studies of LBH589
in this setting are currently underway and are anticipated to
be reported next year. A single report exists of a patient
with MF that achieved normalization of peripheral blood
counts within 6 weeks of treatment with SAHA (Lee 2009).
LBH589 clinical activity has been correlated with
biomarker response including reduction in downstream
substrates of the JAK/STA T pathway (p-STA T3, p-STA T5,
p-AKT, p-ERK1/2, and p-PIM protein levels), reduction in
Bcl-Xl and MCL-1 as well as modest reduction in
JAK2V617F allele burden in treated patients (DeAngelo
et al. 2010). Additionally, Ac-α-tubulin and HSP70 levels
were found to be elevated after treatment with LBH589
which supports the mechanism of both HDAC6 and HSP90
inhibition.
Thrombocytopenia is the major dose-limiting toxicity of
HDACi treatment and can pose a serious clinical risk of
bleeding in the treatment of patients with MF and low
baseline platelet counts. Recently, in vitro studies on
primary murine megakaryocytes and murine and human
cell lines has revealed that the predictable clinical throm-
bocytopenia induced by LBH589 is not an effect on
reduced platelet survival but instead a decrease in propla-
telet formation (Bishton et al. 2011). Reductions in Rho-
GTPase proteins Rac1, CDC42, and RhoA after exposure
to LBH589 are correlated with an increase in phosphory-
lated myosin light chain 2 and postulated to reduce
proplatelet production in megakaryocytes. Studies by
Iancu-Rubin et al. (2010) show that LBH589-induced
thrombocytopenia is also likely due to a reduction in
proplatelet production mediated by hyperacetylation of
tubulin which is an integral component of the microtubule
cytoskeleton and necessary for proplatelet extension. This
work highlights the importance of the impact of HDAC
inhibition on non-histone protein function. The use of a
thrombopoietin mimetic in combination with LBH589 to
support the drug-induced toxicity of thrombocytopenia may
offer an approach that will allow more effective clinical use
in MPN patients that already have low platelet counts at
baseline. Alternatively, LBH589 may prove to be very
useful in the treatment of patients with ET, where reducing
the platelet count would be advantageous.
DNA methyltransferase inhibitors
Two DNMTi, 5-Aza (Vidaza) and DEC (Decitabine) have
been used extensively, and with success, for the treatment
of MDS (Silverman et al. 2002, 2006; Kantarjian et al.
Table 3 Chromatin-modifying agents under investigation for MPN therapy
Agent Brand Name Pharmaceutical
company
Mechanism of action Phase of study
in MPN
Histone deacetylase inhibitors
LBH589 Panobinostat Novartis Class I/II HDAC inhibition I/II
HSP 90 inhibition
ITF2357 Givinostat Italfarmaco Class I/II HDAC inhibition II
HSP90 inhibition
Suberoylanilide hydroxamic acid V orinostat Merck Class I/II HDAC inhibition None
HSP90 inhibition
DNA methyltransferase inhibitors
Azacitidine Vidaza Celgene DNA methyltransferase I inhibition Phase II
Decitabine Dacogen Eisai DNA methyltransferase I inhibition Phase II
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the treatment of MPNs and have been examined in a
number of phase I and II clinical trials. In two phase II
studies, 5-Aza was tested as a 7- and 5-day course every
4 weeks in patients with refractory/relapsing PMF or post-
ET/PV MF (Quintas-Cardama et al. 2008; Mesa et al.
2009b). No significant clinical response was seen although
global hypomethylation was observed. Myelosuppression
was the major adverse event in these two studies. DEC,
however, has shown potential for clinical response in PMF
as well as MF-BP (Mascarenhas et al. 2010; Danilov et al.
2009). In a phase II multi-center study of 20 patients with
PMF treated with low-dose DEC as a subcutaneous
injection, a 37% response rate was seen and two patients
with MF-BP obtained a complete and partial response by
WHO criteria (Odenike et al. 2008). In those patients with
clinical response, a 61% mean reduction in circulating
peripheral blood CD34+ cells was noted. However, no
change in CXCR4 expression was seen. As is seen with 5-
Aza, myelosuppression was the most common toxicity. A
small retrospective study of the combined use of DEC with
gemtuzumab ozogamicin in patients with MF and MF-BP
supports a potential combination therapeutic approach (Al-
Ameri et al. 2010).
Future studies will be designed combining both HDACi
and DNMTi given either concomitantly or in sequence in
MPN patients. Both scientific rationale as discussed above
and clinical experience in the treatment of MDS provides a
strong rationale for this treatment approach in MPNs.
Additionally, as it has become clear that unlike CML which
has a defined pathogenetic mechanism that can be exploited
effectively, the Ph-negative MPNs are indeed more complex
in their pathogenesis. These hematologic malignancies will
likely require a therapeutic strategy including combinations
of drugs that will affect both epigenetic events and
intracellular signaling pathways in an attempt to target the
MPN HSC clone. Studies combining the use of both
HDACi and DNMTi together and with JAK2 inhibitors
are being designed and will almost certainly herald a new
era of combination therapy that will hopefully result in
clinical advances.
Conclusion
The Ph-negative MPNs are a group of myeloid malig-
nancies that have enjoyed a tremendous amount of
attention in recent years due to successive laboratory
based discoveries in molecular pathology stemming from
the discovery of the JAK2V617F mutation in 2005.
There is growing evidence of multiple mutational events
that likely contribute to MPN pathogenesis and influence
disease phenotype. Many of these gene mutations alter
the MPN epigenome, and multiple genes have been
identified as targets of epigenetic deregulation in MPN
cells. Supported by sound scientific rationale, chromatin-
modifying agents have been tested in early phase studies
with a hint of efficacy and will continue to be tested
more rigorously alone and in combination. An MPN-
specific epigenetic signature is evolving and will likely
soon play a vital role in MPN classification, prognosti-
cation, and treatment of these diverse hematopoietic stem
cell neoplasms.
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